Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Cagrilintide

A Study on How NNC0174-1213 Works in People With Overweight or Obesity.

Novo Nordisk · Phase 1 · Completed · Enrollment 178

NCT06719011

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Part A: NNC0174-1213 (SD1-SD5)n/rn/rn/rn/r
Part A: Cagrilintide (SDA and SDB)n/rn/rn/rn/r
Part A: Placebon/rn/rn/rn/r
Part B: NNC0174-1213 (MD1-MD5)n/rn/rn/rn/r
Part B: Cagrilintide (MDA)n/rn/rn/rn/r
Part B: Placebon/rn/rn/rn/r

Not shown

  • Part A: NNC0174-1213 (SD1-SD5): endpoint not reported
  • Part A: Cagrilintide (SDA and SDB): endpoint not reported
  • Part A: Placebo: endpoint not reported
  • Part B: NNC0174-1213 (MD1-MD5): endpoint not reported
  • Part B: Cagrilintide (MDA): endpoint not reported
  • Part B: Placebo: endpoint not reported